<DOC>
	<DOCNO>NCT00256191</DOCNO>
	<brief_summary>Tapestry Pharmaceuticals , Inc. develop novel taxane analog , TPI 287 . TPI 287 synthetically manufacture naturally occur taxanes extract yew start material . The synthesis involve modification taxane side chain overcome multidrug resistance achieve mutant tubulin binding . This study multi-center , dose escalation , sequential group , Phase 1 study evaluate intravenous administration TPI 287 every 21 day cycle .</brief_summary>
	<brief_title>Study TPI 287 Administered Every 21 Days Patients With Advanced Malignancies</brief_title>
	<detailed_description>The primary objective study determine maximum tolerate dose TPI 287 administer every 21 day Phase II clinical trial .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patients must be/have : Histological evidence malignancy Advanced solid tumor recur progress follow standard therapy Failed one prior therapy standard therapy available Ambulatory ECOG 01 estimate life expectancy &gt; 3 month If female , negative pregnancy test If childbearing year , agree use birth control If patient prior radiation therapy brain metastasis , steroid , must stable 1 month Patients exclude : Prior radiation within 4 week Active medical condition organ disease may compromise safety interfere study Clinically significant cardiac comorbidities pulmonary impairment Concomitant therapy need Treated investigational drug within 30 day Tumors involve major artery vein Prior concurrent central nervous system ( CNS ) disease Less 4 week since major surgery Known positive HIV , hepatitis B C Concurrent use aspirin Use thrombolytic agent Uncontrolled hypertension Grade IIIV peripheral vascular disease Pregnant lactate Prior allergic history compound similar chemical composition Inpatients Grade IIIV peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>taxanes</keyword>
	<keyword>multidrug resistance</keyword>
	<keyword>mutant tubulin binding</keyword>
	<keyword>Hodgkin 's Non-Hodgkin 's Lymphoma</keyword>
</DOC>